Skip to main content
Altuviiio logo

HemAssistTM Sanofi Support


We complement the support you provide your ALTUVIIIO patients and their caregivers with access to treatment, education, and financial assistance from Sanofi.

Enroll your patients

Financial assistance

Every person’s situation is different, which is why we work directly with patients to help identify the financial assistance programs for which they may be eligible.

Treatment education

We can help your patients understand more about ALTUVIIIO, as well as offer supplemental administration training and tips to help them start and stay on track with treatment as prescribed.

Access to treatment

From providing reimbursement education to helping navigate insurance coverage with patients, our team works with you and your patients to help get them started on ALTUVIIIO as efficiently as possible.

Financial assistance:

Copay Assistance Program*

HemAssist may be able to help eligible ALTUVIIIO patients gain access to treatment for as little as $0.

Free Trial Program

Patients prescribed ALTUVIIIO for the first time can receive their first 30-day supply treatment generally within 24 to 48 hours with a valid prescription. 
 

Accelerate Free Trial Program

HCPs can initiate ALTUVIIIO treatment for eligible patients to provide a one-time, 30-day supply from their commercial inventory, at no cost to the patient.

Patient Assistance Program

HemAssist’s Patient Assistance Program may be available to help eligible ALTUVIIIO patients who are uninsured, underinsured, or experiencing a temporary loss in insurance coverage.

* Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ALTUVIIIO prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ALTUVIIIO prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.  

Free Trial valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free Trial not valid in Vermont. Claims for free products dispensed through the Free Trial Program shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.  

‡ Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Field Reimbursement Managers (FRMs)

For you:

Our FRMs can help with navigating patient insurance challenges and providing reimbursement education to your office.

Case Managers



For you:

Our case managers are available to assist your patients with navigating insurance coverage and identifying available financial support if eligible.

 

For your patients:

A Case Manager is available to assist with navigating insurance coverage and identifying available financial support for eligible patients.

Clinical Educators (CEs)


For you:

CEs can answer questions about your patient’s condition and treatment and can provide helpful support including disease state education, treatment tips, and supplemental administration training.

 

For your patients:

Your local CE is your point of contact for treatment and disease state education, tips, supplemental administration training, and ongoing support.

Questions? Call 1-833-723-5463, Monday through Friday, 8 AM to 7 PM ET, or request a visit from an ALTUVIIIO Rep. They can connect you with a Case Manager, who can further explain what the ALTUVIIIO assistance programs can offer your patients.

Tools for your patients

Infusion Overview

Doctor Discussion Guide

ALTUVIIIO Patient Brochure: An Overview

Help patients connect with peers

Through the Peer Mentor Program, your patients can connect with a real ALTUVIIIO patient for advice, information about their experience, and more.

Request a Peer Mentor

Keep track of hemophilia with the MicroHealth app

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia. MicroHealth is an app specifically designed to help patients with hemophilia track their treatment and progress and share this information with healthcare providers.

Download MicroHealth Brochure
Microhealth app
icon bubble

Ready to talk about ALTUVIIIO?

Set up time to talk with an ALTUVIIIO Representative to get to know ALTUVIIIO better.

icon finance

Resources for HCPs

Learn about resources and tools for your practice as well as billing and coding information for ALTUVIIIO.

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2403562-v7.0-07/2026 Last Updated: July 2026